CALL FOR ABSTRACTS

★ Abstract Submission Deadline: November 19, 2020
★ Late-Breaking and Clinical Trials
Abstract Submission Deadline: January 11, 2021
TABLE OF CONTENTS

2  Key Dates
3  Welcome
4  Scientific Program
   Plenary Sessions
   Major Symposia
   Advances Sessions
   Forums
   Educational Program
8  Policy Sessions
9  Spotlight on Clinical Trials
10 Professional Advancement Opportunities
11 Continuing Medical Education (CME)
12 Survivor and Patient Advocacy Program
13 Press Coverage and Social Media
14 Financial Support for Attendance
16 Guidelines for Preparation and Submission of Abstracts
19 Abstract Categories
24 AACR Membership Opportunities
26 General Information
28 Annual Meeting Committees

ABOUT THE COVER IMAGE:
©2020 American Association for Cancer Research
Inside of sphere (clockwise): AACR Virtual Special Conference: Epigenticics and Metabolism art; Glioblastoma (iStock); DNA sequencing (Getty)
Foreground of sphere (clockwise): 3D render of T cells attacking cancer cells (Getty); 3D illustration of a method of DNA sequencing (Getty); Medical 3D illustration of a dividing cancer cell (Getty)
### AACR ANNUAL MEETING 2021

#### KEY DATES

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>September 30, 2020</td>
<td>Abstract Submission Opens</td>
</tr>
<tr>
<td>October 13, 2020</td>
<td><strong>Application Deadline: NextGen Stars</strong></td>
</tr>
<tr>
<td>November 12, 2020</td>
<td>Membership Application Deadline for Regular Abstract Sponsors and Scholar-in-Training Award Applicants</td>
</tr>
<tr>
<td>November 19, 2020</td>
<td><strong>Regular Abstract Submission Deadline (11:59 p.m. ET)</strong></td>
</tr>
<tr>
<td>November 19, 2020</td>
<td><strong>Application Deadlines:</strong></td>
</tr>
<tr>
<td></td>
<td>AACR Global Scholar-in-Training Awards</td>
</tr>
<tr>
<td></td>
<td>AACR Minority-Serving Institution Faculty Scholar in Cancer Research Awards</td>
</tr>
<tr>
<td></td>
<td>AACR Minority Scholar in Cancer Research Awards</td>
</tr>
<tr>
<td></td>
<td>AACR Scholar-in-Training Awards</td>
</tr>
<tr>
<td></td>
<td>AACR Women in Cancer Research Scholar Awards</td>
</tr>
<tr>
<td>December 18, 2020</td>
<td>Late-Breaking and Clinical Trials Abstract Submission Opens</td>
</tr>
<tr>
<td>January 6, 2021</td>
<td>Online Itinerary Planner Available</td>
</tr>
<tr>
<td>January 7, 2021</td>
<td>Membership Application Deadline for Late-Breaking and Clinical Trials Abstract Sponsors</td>
</tr>
<tr>
<td>January 11, 2021</td>
<td><strong>Late-Breaking and Clinical Trials Abstract Submission Deadline (11:59 p.m. ET)</strong></td>
</tr>
<tr>
<td>February 1, 2021</td>
<td>Regular Abstract Status Notifications Sent</td>
</tr>
<tr>
<td>February 4, 2021</td>
<td><strong>Submission Deadline: Final Data for Clinical Trial Placeholder Abstracts</strong></td>
</tr>
<tr>
<td>February 10, 2021</td>
<td>Late-Breaking and Clinical Trials Abstract Notifications Sent</td>
</tr>
<tr>
<td>February 22, 2021</td>
<td>Regular Abstract Withdrawal Deadline</td>
</tr>
<tr>
<td>March 9, 2021</td>
<td>Late-Breaking and Clinical Trials Abstract Withdrawal Deadline</td>
</tr>
<tr>
<td>March 17, 2021</td>
<td>Annual Meeting App Available for Download</td>
</tr>
<tr>
<td>April 9, 2021</td>
<td><strong>AACR Annual Meeting Begins (12:00 p.m. ET)</strong></td>
</tr>
<tr>
<td>April 9, 2021</td>
<td>Late-Breaking and Clinical Trials Abstract Texts Posted to Online Itinerary Planner and Meeting App</td>
</tr>
</tbody>
</table>
Dear Members and Friends of the AACR,

We are pleased to announce the Call for Abstracts for the 112th Annual Meeting of the American Association for Cancer Research (AACR). Reflecting the theme of this year’s meeting, “Discovery Science Driving Clinical Breakthroughs,” the scientific program will span the broad spectrum of cancer science and medicine from basic, translational, and clinical research including cancer health disparities; to early detection, interception, prevention, and population science; to regulatory science and policy.

The Opening Plenary Session will address the theme of the meeting and will include presentations on lineage tracing of tumor metastasis, tumor metabolism, genomic sequencing in diverse populations, immune surveillance, antitumor immune response, and clinical implications. New this year is the Discovery Science Plenary Session, which will focus on the mechanisms, impact, and exploitation of cancer chromosomal instability for potential therapeutic intervention. Also, a comprehensive educational program of more than 60 educational sessions and methods workshops, covering a wide array of disciplines and new technologies, is currently under development.

Major progress against cancer has been realized over the past few decades due to remarkable scientific advances and multidisciplinary collaborations, and during this year a record number of new cancer treatments were approved by the U.S. Food and Drug Administration. However, during the COVID-19 pandemic, many labs were forced to close, and clinics have needed to shift resources and refocus efforts to combat this enormous public health crisis. There is now much concern that the delays in cancer screening, diagnosis, and treatment because of the COVID-19 pandemic will have a significant negative impact on the pace of progress against cancer and on cancer patient outcomes. Now more than ever it is critically important to focus our collective efforts and resources on our mission to prevent and cure all cancers.

Despite these challenges, this has been a transformative year for the global cancer research community – one that has resulted in a new wave of scientific innovation that will be reflected in our Annual Meeting program. The year 2021 will be an exciting time for us to celebrate the 50th Anniversary of the signing of the National Cancer Act. The signing of this Act was a pivotal moment in history, as it has led to the formation of highly impactful comprehensive cancer centers in the U.S., the development of education and training programs for early-career laboratory and clinical investigators, increased funding for innovative cancer research, and many cancer breakthroughs that have saved millions of lives from the disease.

Proffered oral and poster presentations selected from submitted abstracts are a vital part of our Annual Meeting. For your interest, a new abstract category for research on COVID-19 and cancer has been added to our Call for Abstracts. We look forward to receiving your submissions and to providing an interactive venue for you to share your important work. Your participation in the 2021 Annual Meeting will not only be a welcome addition to the program, but it will also maximize collaborations, stimulate creative thinking about how to accelerate progress against cancer, and contribute greatly to the cause.

The regular abstract deadline is November 19, 2020. Our proffered program also features special oral presentation opportunities in several Clinical Trial Plenary Sessions for abstracts reporting on high-impact clinical trials. The deadline for late-breaking abstracts and clinical trial abstracts is January 11, 2021.

Please note that recently, the AACR Board of Directors approved an expansion of the abstract sponsorship privileges for certain AACR member types. We encourage AACR members to use their additional privileges to sponsor abstract submissions from their mentees and nonmember colleagues. Please view the details of these expanded privileges on page 18.

The AACR will also continue to offer special presentation opportunities for early-career scientists. All AACR Associate Members, as well as Active Members at the assistant professor level or equivalent, may apply to the NextGen Stars Program to be considered for the honor of presenting their work in one of the major sessions during the meeting. Interested members must submit an abstract along with supporting materials by October 13, 2020. Please check the AACR website (AACR.org/AACR2021) regularly for program updates and other meeting announcements.

During these difficult times our heartfelt sympathies are extended to everyone who has been impacted by this global health crisis. It is our sincere hope that we will all be able to gather in person in 2021 to discuss your innovative work across the full spectrum of cancer research.

We look forward to receiving your abstract submissions and to your active participation in AACR Annual Meeting 2021.

With best wishes and regards,

Antoni Ribas, MD, PhD, FAACR
President, 2020-2021

Charles Swanton, FRCP, BSc, PhD, FAACR
Chair, 2021 Program Committee
WHY YOU SHOULD ATTEND THE WORLD’S MOST IMPORTANT CANCER RESEARCH MEETING

The AACR Annual Meeting highlights the work of the greatest minds in cancer science and medicine from institutions all over the world. This meeting presents the many scientific discoveries across the breadth of cancer research—from prevention, early detection, and interception; to cancer biology and genetics, translational, and clinical studies; to survivorship, population science, and advocacy. You will be exposed to the latest developments in all areas of cancer research, form new collaborations, and learn how to apply exciting new concepts, tools, and techniques to your own research.

This year’s program, with the theme of “Discovery Science Driving Clinical Breakthroughs,” will be a comprehensive, cutting-edge scientific event that you will not want to miss!

PROGRAM IN PROGRESS

Beginning at 3:00 p.m. on Friday, April 9, and continuing until 3:30 p.m. on Saturday, April 10, 2021, a program of Educational Sessions and Methods Workshops will be presented. An Educational Program Pass granting access to the complete educational program will be available for purchase when registration opens. On Saturday at 3:45 p.m. an exciting new Discovery Science Featured Plenary Session will be open to all registrants. The Opening Ceremony and the Opening Plenary Session will take place on Sunday morning, April 11. The meeting will conclude at 1:30 p.m. on Wednesday, April 14. Abstracts submitted for the regular (November 19, 2020) or late-breaking and clinical trials (January 11, 2021) submission deadlines will be considered for short talks or ePoster presentations. The 2021 Program in Progress follows; additional exciting and timely invited sessions are being developed and will be posted at AACR.org/AACR2021.

PLENARY SESSIONS

Saturday, April 10, 2021

DISCOVERY SCIENCE PLENARY SESSION: MECHANISMS, IMPACT, AND EXPLOITATION OF CANCER CHROMOSOMAL INSTABILITY

David Pellman, Dana-Farber Cancer Institute, Boston, MA
Angelika Amon, Massachusetts Institute of Technology, Cambridge, MA
Stephen P. Jackson, University of Cambridge, Cambridge, United Kingdom
Additional speaker to be announced.

Sunday, April 11, 2021

OPENING PLENARY SESSION: DISCOVERY SCIENCE DRIVING CLINICAL BREAKTHROUGHS

Chair: Charles Swanton, The Francis Crick Institute, London, United Kingdom
Jonathan S. Weissman, University of California, San Francisco, CA
Karen H. Vousden, The Francis Crick Institute, London, United Kingdom
Matthew G. Vander Heiden, Massachusetts Institute of Technology, Cambridge, MA
Melissa B. Davis, Weill Cornell Medical College, New York, NY
Mark A. Dawson, Peter MacCallum Cancer Centre, Melbourne, Australia
Zhijian James Chen, UT Southwestern Medical School, Dallas, TX
Monday, April 12, 2021

UNDERSTANDING THE MOLECULAR AND MICROENVIRONMENTAL DETERMINANTS OF CANCER

Chair: Christina Curtis, Stanford University, Stanford, CA
Garry P. Nolan, Stanford University School of Medicine, Stanford, CA
Serena Nik-Zainal, University of Cambridge, Cambridge, United Kingdom
Ross L. Levine, Memorial Sloan Kettering Cancer Center, New York, NY
Jérôme Galen, INSERM, Paris, France

Tuesday, April 13, 2021

CANCER BIOLOGY AND THE CHANGING THERAPEUTIC LANDSCAPE

Chair: Sheila A. Stewart, Washington University, St. Louis, MO
Tony Hunter, Salk Institute, La Jolla, CA
William G. Kaelin, Jr., Dana-Farber Cancer Institute, Boston, MA
Olufunmilayo I. Olopade, University of Chicago Medicine Comprehensive Cancer Center, Chicago, IL
Dennis J. Slamon, UCLA David Geffen School of Medicine, Los Angeles, CA

Wednesday, April 14, 2021

LEVERAGING THE IMMUNE SYSTEM IN THE WAR ON CANCER

Chair: Nina Bhardwaj, Icahn School of Medicine at Mount Sinai, New York, NY
Anjana Rao, La Jolla Institute for Immunology, La Jolla, CA
Sergio A. Quezada, University College London Cancer Institute, London, United Kingdom
Michel Sadelain, Memorial Sloan Kettering Cancer Center, New York, NY
Additional speaker to be announced.

MAJOR SYMPOSIA

AACR-Bayard D. Clarkson Symposium on Stem Cells, Leukemia, and the Niche
Advances in Cancer Nanotechnology
Alternative DNA Repair Pathways and Their Drug Targets
Artificial Intelligence in Cancer Imaging
Artificial Intelligence/Machine Learning in Cancer Research and Care: Progress and Opportunities
Cancer Immunometabolism
Colorectal Cancer Interception: Immunologic and Pharmacologic Advances
COVID-19 and Cancer Research
Cytokine Receptors in Immuno-oncology: Discovery, Analysis, and Modulation
Deubiquitylating Enzymes as Targets for Cancer Therapy
Developing Rational Combinations of Targeted Drugs
Diet, Clock, and Cancer
Drugging KRAS
Engineering and Modulating Natural Killer Cells for Cancer Immunotherapy
Familial Predisposition: Precision Medicine and Targeted Therapy
From ‘Omics Data to Prognostic and Predictive Biomarkers
Functional Precision Medicine in Cancer
Germline Influence on Immunotherapy Outcomes
Implications of Clonal Hematopoiesis in Human Health
Improving Therapy through Normalization of the Tumor Microenvironment
Matrix, Exosomes, and TME Cells in the Metastatic Niche
Mechanisms and Biomarkers of Response and Resistance to Immunotherapy
Metabolism and Chromatin Deregulation in Cancer and Cancer Heterogeneity
Modeling Metastatic Progression in the Mouse
Molecular Imaging
Neoadjuvant Immunotherapy for Melanoma and Other Cancers
New Approaches to Chimeric Antigen Receptor Engineering
New Combinations of Targeted Therapies and Immunotherapies
Next Frontiers in Adjuvant Therapy
Next-Generation Epigenetic Drugs
Options and Opportunities for Treating Metastasis
Paracrine Signaling in Cancer
Phase Separation, Transcription, and Cancer
Progress from Personalized Cancer Vaccine Trials
T Cells in Cancer
The Cancer Dependency Map
The Clinical Proteomic Tumor Analysis Consortium: Building a Proteogenomic Atlas of Cancer
The Microbiome in Cancer Therapy: Hype or Hope?
The Tumor Microbiome and Its Role in Oncogenesis and Modulating Therapy Response
Toward Engineering of Neoantigen-Specific T-Cell Therapies
Tumor Cell Plasticity and Resistance to Cancer Therapies
Tumor Hypoxia and Genetic Instability: New Mechanisms and New Targets
When Is Transforming Growth Factor Beta Targetable?
AACR-ASCO Joint Session: Targets in the Treatment of Renal Cell Cancer
AACR-CSCO Joint Symposium: Single-Cell Analysis—Changing the Landscape of Cancer Research
AACR-JCA Joint Session: Tracking Tumor Evolutionary Dynamics: From Initiation through Metastasis
AACR-ONS Special Session: Symptom Science

DNA Damage Response (DDR) Treatment: Evolving Diagnostic Approaches, Understanding of Replication Stress, and Resistance Mechanisms to DDR Targeting Therapies
Hybrid Technologies for Cancer Imaging, Theraonostics, and Image-Guided Interventions
Management of Toxicity of Immune Cell Therapy
Noninvasive Monitoring of Minimal Residual Disease with Liquid Biopsies: Toward Real-Time Treatment Decision-Making
Proton Therapy and FLASH Irradiation
Targeting Transcriptional Cyclin-Dependent Kinases in Cancer
Translational Canine Models Advancing Immunotherapy and Immunogenomics
Understanding and Overcoming Resistance to Third Generation EGFR and ALK Inhibitors

ADVANCES IN ORGAN SITE RESEARCH

Advances in Endometrial Cancer
Advances in Sarcoma Therapy
Developing More Effective Treatments for Triple-Negative Breast Cancer
Diffuse Large B-Cell Lymphoma
Emerging Concepts in Liver Cancer Research
Next-Generation Treatments for Melanoma: Building on Success
Pathways to Early Detection of Pancreatic Cancer
Solid Tumor Brain Metastasis
Targeting Signaling Pathways in Colorectal Cancer
Therapeutic Advances in Biliary Tract Cancers
Therapeutic Vulnerabilities and Resistance Mechanisms in Estrogen Receptor-Positive Breast Cancer

ADVANCES IN DIAGNOSTICS AND THERAPEUTICS

Advances in Drug Delivery
Computational Methods for Immunogenomics and Precision Oncology
Diagnostic Tests for Immunotherapy: Current CLIA Lab Testing and Future Directions

DNA Damage Response (DDR) Treatment: Evolving Diagnostic Approaches, Understanding of Replication Stress, and Resistance Mechanisms to DDR Targeting Therapies
Hybrid Technologies for Cancer Imaging, Theraonostics, and Image-Guided Interventions
Management of Toxicity of Immune Cell Therapy
Noninvasive Monitoring of Minimal Residual Disease with Liquid Biopsies: Toward Real-Time Treatment Decision-Making
Proton Therapy and FLASH Irradiation
Targeting Transcriptional Cyclin-Dependent Kinases in Cancer
Translational Canine Models Advancing Immunotherapy and Immunogenomics
Understanding and Overcoming Resistance to Third Generation EGFR and ALK Inhibitors

ADVANCES IN ORGAN SITE RESEARCH

Advances in Endometrial Cancer
Advances in Sarcoma Therapy
Developing More Effective Treatments for Triple-Negative Breast Cancer
Diffuse Large B-Cell Lymphoma
Emerging Concepts in Liver Cancer Research
Next-Generation Treatments for Melanoma: Building on Success
Pathways to Early Detection of Pancreatic Cancer
Solid Tumor Brain Metastasis
Targeting Signaling Pathways in Colorectal Cancer
Therapeutic Advances in Biliary Tract Cancers
Therapeutic Vulnerabilities and Resistance Mechanisms in Estrogen Receptor-Positive Breast Cancer

ADVANCES IN DIAGNOSTICS AND THERAPEUTICS

Advances in Drug Delivery
Computational Methods for Immunogenomics and Precision Oncology
Diagnostic Tests for Immunotherapy: Current CLIA Lab Testing and Future Directions
ADVANCES IN PREVENTION, EARLY DETECTION, AND INTERCEPTION

Connecting the Tumor Microenvironment with the Macroenvironment in Cancer Cachexia

Interception of Preneoplasia

Molecular Targets of Precision Prevention and Interception

Panel on Rural Cancer Control

Radiation-Induced Cancers and Cancer Survivorship

ADVANCES IN THE SCIENCE OF CANCER HEALTH DISPARITIES

Carcinogenic Exposures and Global Cancer Prevention

Pan-Cancer Distinctions in Tumor Biology across Ethnicity and Genetic Ancestry

Precision Medicine in Underserved Populations

FORUMS

Are Antitumor T Cells Exhausted or Dysfunctional? Does It Matter?

Are There Cancer Stem Cells?

Biostatistics Debate: Should Science Be Guided by P-Values?

Cancer Cell Dormancy: The Current Paradigm and the Challenges Ahead to Develop New Therapies

CAR T-Cell Therapy or T-Cell Engager?

Data Science and Machine Learning: Will They Revolutionize Cancer Cure and Research?

Embracing Entrepreneurship in Cancer Research

Microbiome Pandemonium: Checkpoints and the Microbiome

Patient-Derived Models for Cancer

The Myths and Realities of the Abscopal Effects

What Is the Role for Oncolytic Viruses in Cancer Treatment?

EDUCATIONAL PROGRAM: EDUCATIONAL SESSIONS AND METHODS WORKSHOPS

Educational programming will begin on Friday, April 9, at 3:00 p.m. and continue through 3:30 p.m. on Saturday, April 10. The Educational Program is an integral part of the meeting and provides attendees with an opportunity to expand their knowledge base. Meeting registrants will be able to purchase an Educational Program Pass granting access to the complete educational program of more than 65 unique sessions covering all areas of cancer research, including the popular multisession programs noted below. More information about the Educational Program and the Educational Program Pass will be available at AACR.org/AACR2021.

★ Tumor Immunology and Immunotherapy for Nonimmunologists. Annually, this two-part series combines a comprehensive review of a hot topic in the field with a roundtable session that enables attendees to participate in group discussions with leading experts in the field.

★ Chemistry to the Clinic. This three-part series provides attendees with foundational knowledge of critical elements of the drug development process, such as lead optimization, identification of targets, and drug modalities.

★ Clinical Trial Design. Over the course of three consecutive sessions, this Methods Workshop will provide attendees with a historical and methodologic understanding of clinical trials and demonstrate how to design an appropriate trial to answer the scientific questions presented by emerging treatments.

Additional details will be posted at AACR.org/AACR2021.
Decisions made by policymakers in Washington, DC, have a direct impact on cancer research and the progress being made against cancer in the United States and throughout the world. The AACR sponsors sessions with policymakers, academic researchers, patient advocates, cancer survivors, and industry representatives to foster dialogue about emerging topics in science and health policy, and regulatory science and policy.

The Science and Health Policy Track includes sessions that will provide attendees with an opportunity to learn about how policy impacts science and vice versa. Science policy sessions will examine the current political environment affecting federal funding for the NIH and NCI, including highlighting ways for scientists to get involved in advocating for robust, sustained, and predictable budget increases. Health policy sessions will explore how scientific evidence can inform policy on cancer prevention and control and what impact policies are having on patients and communities. Past health policy sessions have covered topics such as e-cigarettes and tobacco control measures, the Affordable Care Act, and ways to prevent and control pathogen-related cancers, such as increasing the use of the human papillomavirus (HPV) vaccine.

The Regulatory Science and Policy Track includes informative sessions designed to highlight recent regulatory developments and provide an open forum for the consideration of issues that the FDA faces as the agency seeks to accelerate the pace of approval of safe and effective treatments for patients with cancer. These sessions offer an opportunity for attendees to discuss cutting-edge issues in cancer drug, biologic, and diagnostic regulation with stakeholders from academia, industry, advocacy, and government. Past regulatory science and policy topics have included strategies for increasing participation of underrepresented populations in clinical trials, guidance for using real-world evidence to support clinical trials during the COVID-19 pandemic, regulatory considerations for developing liquid biopsy tests, implications of site-agnostic therapy approval for drug development, and applications for artificial intelligence/machine learning in regulatory decision-making.

The Science of Survivorship Track includes sessions highlighting new and high-value areas of research to address the array of challenges facing long-term cancer survivors. Sessions invite trans-sector discussion among the survivor and advocacy communities, basic and clinical researchers, industry representatives, health care providers, and government officials. Past science of survivorship topics have included aging and cancer, long-term survivorship and vulnerable populations, development of new survivorship models, patient-reported outcomes, data sharing, and patient engagement.
SUBMIT YOUR CLINICAL TRIALS ABSTRACTS TO THE AACR ANNUAL MEETING 2021

Become a part of our growing clinical research program at the Annual Meeting and help us showcase how discovery science continues to transform the lives of cancer patients.

WHY YOU SHOULD SUBMIT
★ Numerous and unique oral presentation opportunities
  • Four Clinical Trials Plenary Sessions offering companion presentations discussing the science behind the trials presented
  • Three Clinical Trials Minisymposia
★ Poster presentations (enhanced e-Posters with opportunities for engagement)
★ Opportunities for extensive national media coverage through the AACR press program
★ Opportunities to simultaneously present your work and publish a manuscript in a high-impact AACR journal
  • Indicate your intention to submit a manuscript during the abstract submission process.
  • Contact pubs@aacr.org with any questions.
★ No restrictions on presenters if the presentation is CME-compliant

WHAT TO SUBMIT
★ Any phase (I, II, III, or any combination) abstract from national or international clinical trials
★ Promising ongoing trials, or unique trial designs that have not yet yielded results, to the Clinical Trials in Progress category (CT08)
★ Encore clinical trials presentations that have been presented solely in abstract form, including publication in conference proceedings. Submissions must include significant additional data from the previous presentation (as determined by the review committee).
★ COVID-19 and cancer clinical trials to the COVID-19 and Cancer (COVID06) or Clinical Trials (CT07) categories.
★ See pages 21-22 for clinical trials (CT) abstract categories and visit AACR.org/AACR2021 for submission guidelines.

WHEN TO SUBMIT
★ Submit your completed or placeholder abstract(s) by the January 11, 2021 deadline for clinical trials and late-breaking abstracts. The clinical trials (CT) abstract categories will not be available for submissions for the November 19, 2020 deadline.
★ Final results and conclusions for placeholder abstracts are due by February 4, 2021.

AACR VIRTUAL ANNUAL MEETINGS I AND II 2020

30 TRIALS IN CLINICAL PLENARY SESSIONS
104 TRIALS IN POSTER SESSIONS
50 TRIALS IN PROGRESS IN POSTER SESSIONS
In support of its mission to promote the education and training of cancer scientists and clinicians and to cultivate a highly skilled and diverse cancer research workforce, the AACR provides Annual Meeting attendees at all career stages—from high school and undergraduate students to senior investigators—with opportunities to enhance and advance their careers. For more information about any of the professional development opportunities that follow, visit AACR.org/AACR2021 and click on the “Professional Development Opportunities” tab.

**NEXTGEN STARS**

Early-career scientists can apply to give a presentation in a Major Symposium or Advances Session at the AACR Annual Meeting 2021. Speaking slots are limited and are only available to AACR Associate Members and to AACR Active Members who are not above the level of assistant professor or equivalent. The NextGen Stars program provides an exciting opportunity to increase the visibility of early-career scientists at the AACR Annual Meeting and to support the professional development and advancement of those selected to speak.

The deadline to submit applications is **12:00 p.m. U.S. ET, October 13, 2020.** Applications consist of an extended abstract (limit 8,000 characters), a CV, and a letter of recommendation from a P.I., department head, or another mentor who is familiar with the applicant’s work. Applicants selected as NextGen Stars for 2021 will receive travel support and complimentary registration for the meeting. Details can be found at AACR.org/AACR2021 under the “NextGen Stars” tab.

**PROFESSIONAL ADVANCEMENT SESSIONS**

**Exclusive Member Benefit**

Professional Advancement Sessions have long been an integral part of the AACR Annual Meeting experience, representing the AACR’s dedication to the education, training, and career advancement of cancer research investigators at all stages of their careers. Each year, several interactive and engaging professional development and career advancement opportunities are organized to provide important skills to investigators at all levels, from students to senior faculty.

All Professional Advancement Sessions are free and exclusive to AACR members. There is no cost to join the AACR as a Student Member (high school students and undergraduates) or Associate Member (graduate students, medical students and residents, and clinical and postdoctoral fellows who are enrolled in education or training programs that could lead to a career in cancer research). If you are not an AACR member, you are strongly encouraged to join and take advantage of being able to attend these sessions and the many other benefits of membership, including the privilege of sponsoring abstracts, and reduced member registration rates for the Annual Meeting 2021. Visit AACR.org/Membership to apply today!

Professional Advancement Sessions to be held at the Annual Meeting 2021 will be announced in the fall. Visit AACR.org/PAS for session updates, including opportunities for physician-scientists and early-career and early-stage investigators.
The AACR’s Continuing Medical Education (CME) Program brings the latest cancer research from “bench to bedside and back.” The AACR has been awarded Accreditation with Commendation status by the Accreditation Council for Continuing Medical Education (ACCME). The AACR CME Program consists of educational interventions designed to encourage the analysis and discussion of the latest findings in all areas of basic, translational, and clinical cancer research not only among researchers, but also by engaging clinicians in this scientific discourse. The AACR is committed to advancing the ability of clinicians to apply critical aspects of cancer research to the clinical practice of oncology to aid in the detection, diagnosis, treatment, and prevention of cancer. The AACR Annual Meeting 2021 will be a Continuing Medical Education Activity and **AMA PRA Category 1 Credits™** will be available. This is a great opportunity to complete your required credit hours.

**MEET YOUR MOC POINT REQUIREMENTS**

If you are a physician, you can meet your Maintenance of Certification (MOC) point requirements at the AACR Annual Meeting 2021. The meeting is CME/MOC accredited. Successful completion of the CME activity enables you to earn MOC points of the American Board of Internal Medicine’s (ABIM) Maintenance of Certification program.
AACR’S COMMITMENT TO SURVIVORS AND PATIENT ADVOCATES

The voices of patients with cancer have never been more important than in today’s environment, especially as patients are partnering with researchers by selflessly donating tissue and personal data to advance progress. Additionally, patient advocates play a crucial role in educating the public about new research discoveries, serving on committees and panels to inform cancer research and regulatory policies, increasing awareness among legislators, and raising precious funds for cancer research.

The AACR recognizes and celebrates the contributions of survivors and patient advocates to cancer research and policy and welcomes their attendance and participation at the AACR Annual Meeting.

Discounted registration rates are available for patient advocates.

AACR SCIENTIST↔SURVIVOR PROGRAM

A special advocacy program that the AACR hosts each year is the AACR Scientist↔Survivor Program (SSP), which is now in its 23rd year. Led admirably since its inception by Anna D. Barker, PhD, of the Lawrence J. Ellison Institute for Transformative Medicine of USC, SSP is designed to build enduring partnerships among the leaders of the scientific, cancer survivor, and patient advocacy communities worldwide. The program has a competitive application process and occurs twice each year, with the larger program being held in conjunction with the AACR Annual Meeting.

This unique program provides an opportunity for patient advocates to learn about cancer research and to interact with scientists, physicians, health care professionals, and other advocates.

Specifically, patient advocate representatives come together to discuss the latest findings in cancer research, foster collaborative interdisciplinary partnerships, and promote progress in new research areas in the cancer field. Advocates benefit from special scientific lectures in lay terms; stimulating small group discussions; and other opportunities to exchange information on key aspects of cancer research, survivorship, advocacy, and public policy.

If you are interested in applying for this year’s SSP, please visit AACR.org/SSP2021 or contact us at advocacy@aacr.org.

Patient advocates can also engage with the AACR in many ways throughout the year, including through AACR’s magazine Cancer Today; the AACR Foundation, the annual AACR Cancer Progress Report; and by participating in advocacy days on Capitol Hill.
ATTRACTING JOURNALISTS WORLDWIDE, GENERATING MAJOR NEWS COVERAGE

The AACR is the authoritative resource and voice for cancer research, and the AACR Annual Meeting garners the best in national and international news coverage. The AACR Virtual Annual Meetings I and II, held in April and June 2020, attracted a total of 174 registered reporters. The two meetings showcased innovative clinical, translational, and basic research and generated nearly 2,500 media clips in leading consumer and trade outlets including The Associated Press, The New York Times, The Washington Post, Reuters, STAT, and Science, among many others.

All abstracts accepted for presentation at the meeting will be considered for inclusion in the official AACR Annual Meeting 2021 press program. For more information on the AACR Annual Meeting press program, please contact Julia Gunther at julia.gunther@aacr.org or Rick Buck at rick.buck@aacr.org.

UTILIZING SOCIAL MEDIA TO AMPLIFY THE CONVERSATION

The AACR Virtual Annual Meetings I and II 2020 also generated significant social media activity in the cancer research community. Social media highlights included:

**AACR Virtual Annual Meeting I 2020:**

- 2,758 people joining the conversation on Twitter
- 9,003 total tweets using the #AACR20 hashtag
- 45,427,000 total impressions

**AACR Virtual Annual Meeting II 2020:**

- 2,307 people joining the conversation on Twitter
- 7,065 total tweets using the #AACR20 hashtag
- 42,426,000 total impressions
AACR ANNUAL MEETING 2021
FINANCIAL SUPPORT FOR ATTENDANCE

Through the generosity of its loyal supporters and grants from the National Cancer Institute (NCI), the AACR is pleased to provide financial support to meritorious undergraduate students and early-career scientists residing anywhere in the world, and also to members of minority groups residing in the United States and Canada that have been traditionally underrepresented in cancer research and biomedical science, to assist them in attending the AACR Annual Meeting. Detailed information about these award programs, including eligibility and selection criteria, can be found by visiting AACR.org/AACR2021 and clicking on the “Financial Support for Attendance” link.

AACR SCHOLAR-IN-TRAINING AWARDS

Exclusive Member Benefit

Scholar-in-Training Awards are available for Associate Members in good standing who are the presenters of meritorious abstracts at the AACR Annual Meeting. These awards are made possible by the generosity of supporting foundations and corporations. Nonmember graduate students, medical students and residents, clinical fellows or equivalent, and postdoctoral fellows who wish to apply for a Scholar-in-Training Award should submit their AACR membership applications by November 12, 2020. The AACR Membership Application Form is available on the AACR website at AACR.org/Membership. To apply for a Scholar-in-Training Award, an applicant must first submit an abstract, and then complete a separate award application. For details of the application process and the selection criteria, please visit AACR.org/SITA. Application deadline: November 19, 2020.

AACR GLOBAL SCHOLAR-IN-TRAINING AWARDS

Global Scholar-in-Training Awards (GSITA) of $2,000 are available for eligible early-career investigators in countries building cancer research capacities. Applicants must submit an abstract to the AACR Annual Meeting 2021 and then complete a separate GSITA application. Applicants must be Associate Members of the AACR in good standing (membership current through 2020). Nonmember graduate students, medical students and residents, clinical fellows or equivalent, and postdoctoral fellows who wish to apply for a GSITA should submit a Membership Application Form by November 12, 2020 before submitting their GSITA application. For additional details and a list of eligible developing countries, visit AACR.org/GSITA. Application deadline: November 19, 2020.

AACR-MINORITIES IN CANCER RESEARCH (MICR)-SPONSORED AWARDS

Minorities in Cancer Research (MICR)—a membership group within the AACR—is working to increase the number, participation, visibility, and recognition of minority scientists in cancer research. The AACR Minority and Minority-Serving Institution Faculty Scholar Awards and Minority Scholar Awards are two of several programs sponsored by MICR in support of its mission. These awards are generously supported by the NCI Center to Reduce Cancer Health Disparities. To learn more, please visit AACR.org/MICR or send an email to micr@aacr.org.

AACR Minority and Minority-Serving Institution (MMSI) Faculty Scholar in Cancer Research Awards:

Full-time minority faculty and faculty of Minority-Serving Institutions (Historically Black Colleges and Universities [HBCUs], Hispanic-Serving Institutions [HSIs], American Indian Tribally-Controlled Colleges and Universities [AITCCUs], and other postsecondary institutions as defined by the U.S. Department of Education) who present a proffered paper at this conference are encouraged to apply for this meritorious scholar award for travel. Supported by a generous grant from the Center to Reduce Cancer
Health Disparities of the NCI, the purposes of these awards are to increase the scientific knowledge base of minority faculty and faculty at MSIs, to encourage them in their research, and to assist in inspiring their students to pursue careers in cancer research. Only citizens of the United States or Canada or scientists who are permanent residents of these countries may receive one of these awards. For details or to submit an application, visit AACR.org/MSI. Application deadline: November 19, 2020.

AACR Minority Scholar in Cancer Research Awards: Presenters of a proffered paper who are full-time predoctoral (graduate or medical) students, residents, and clinical or postdoctoral fellows who are engaged in cancer research or have the training and potential to make contributions to this field are encouraged to apply for this meritorious scholar award for travel. Supported by a generous grant from the Center to Reduce Cancer Health Disparities of the NCI, this program applies only to racial/ethnic minority groups that have been identified by the NCI as being traditionally underrepresented in cancer and biomedical research, e.g., African American/Black, Alaskan Native, Hispanic/Latino, Native American, and Native Pacific Islander. Only citizens of the United States or Canada or scientists who are permanent residents of these countries may receive one of these awards. For details or to submit an application, visit AACR.org/MSA. Application deadline: November 19, 2020.

AACR-WOMEN IN CANCER RESEARCH (WICR) SCHOLAR AWARDS

The AACR-Women in Cancer Research (WICR) Scholar Award is a highly competitive award recognizing WICR members who are scientists-in-training and presenters of meritorious scientific papers at the AACR Annual Meeting. The purpose of this award is to increase the scientific knowledge base of WICR members and to encourage them to pursue careers in cancer research. All graduate students, medical students, residents, clinical fellows, and postdoctoral fellows are welcome to apply. For details or to apply, visit AACR.org/WSA. Application deadline: November 19, 2020.
AACR Abstract Submission System. Authors must submit abstracts for presentation at the Annual Meeting 2021 using the AACR Abstract Submission System, which will be available at AACR.org/AACR2021 beginning September 30, 2020. You can create, modify, and submit abstracts until the November 19, 2020, abstract deadline. Complete instructions on the use of the AACR Abstract Submission System will be provided on the website.

Note for 2021: Submit your abstract detailing how you use AACR Project GENIE data by the November 19, 2020, deadline for an opportunity to be featured in a special session during the Annual Meeting 2021. Simply include GENIE as a keyword during the submission process.

The Abstract Submission System has been optimized for the current versions of most browsers:
- **Google Chrome:** Version 23.0 or higher
- **Internet Explorer:** Version 9.0 or higher
- **Mozilla Firefox:** Version 27.0 or higher
- **Safari:** Version 7.1 or higher
- **Microsoft Edge:** Version 79.0 or higher

Browsers should be set to enable JavaScript and to accept cookies. Users who need assistance in properly updating and configuring their browsers should contact Abstract Submission Customer Service at 217-398-1792 or aacr@support.ctimeetingtech.com.

Responsibilities of Authors. By submitting an abstract for presentation at the AACR Annual Meeting, abstract authors agree and/or attest to the following:

**Support for Abstract/Verification of Authorship.** All authors accept individual responsibility for the accuracy and integrity of statements in their abstract, and the submitting author is required to ensure that all authors have confirmed that all statements are an accurate reflection of the presented data and have agreed to the submission of the abstract and to their being listed as contributors prior to submission. Authors will be notified of their inclusion on an abstract via email.

**Sponsorship of Abstracts.** The submitting author must provide the name of an AACR member who has agreed to sponsor the abstract, and the submitting author must attest that the permission of the member sponsor has been secured prior to initiating an abstract submission. See page 18 for Abstract Sponsorship Regulations.

**Transfer of Copyright.** On behalf of all authors, the submitting author must assign and transfer copyright for the abstract to the AACR.

**Presentation of Abstracts.** The submitting author for each abstract must designate a presenter who agrees to register for the meeting and attend the corresponding session to discuss in detail the research presented in the published abstract. If the assigned presenter cannot attend the meeting, the authors are expected to designate a replacement or withdraw the abstract (see page 17).

**Confirmation of No Prior Publication/Presentation.** Authors who submit an abstract confirm that they have not previously published these data, that they have not previously presented them at a large national annual scientific meeting, and that they are not planning to present or publish them prior to the dates of the AACR Annual Meeting 2021.

Exception: Encore presentations are permitted for clinical trials abstracts that are submitted for the January 11, 2021, clinical trials deadline. During the submission process, authors of encore clinical trials abstracts must provide the date and name of the meeting at which the original trial abstract was presented.

**Content of Abstracts.** Each abstract should contain (a) an introductory sentence indicating the purposes of the study; (b) a brief description of pertinent experimental procedures; (c) a summary of the new, unpublished data; and (d) a statement of the conclusions.

Abstracts should be carefully proofread to avoid errors in the published literature. American spelling should be used throughout; for more information regarding American spelling, please refer to *Scientific Style and Format: The CSE Manual for Authors, Editors, and Publishers, Eighth Edition* (Council of Science Editors, 2014).

**Abstract Control Number.** An Abstract Control Number (e.g., 21-A-1234-AACR) will be assigned to each abstract submitted online and will be listed on all email correspondence regarding the abstract. Please refer to the Abstract Control Number in any abstract communications.

**Financial Relationships of Coauthors.** Per ACCME regulations, the AACR must collect information on the financial relationships of all meeting presenters and abstract authors. You will be asked to disclose your financial relationships and the financial relationships...
of each of your coauthors. For more information on financial relationships, visit AACR.org/CME.

**Sponsor Permission and Information.** Each abstract must be sponsored by an AACR member. You must secure the permission of the sponsor before submitting the abstract. For details, see the “Abstract Sponsorship Regulations” on page 18.

**Length of Abstracts.** The combined length of the abstract body, title, and tables may not exceed 2,600 characters, not including spaces and the author string. Tables count for 800 characters against the limit. Submission cannot be completed for abstracts that exceed this limit.

**Abstract Category, Subcategory, and Subclassification.** You must select a category, subcategory, and subclassification for your abstract. See pages 19-23 for details.

**Disclosure of Chemical Structures.** At the time of abstract submission, the submitting author is required to state whether chemical compounds were used in the scientific work to generate the data in the proffered paper. Chemical compounds are defined as low-molecular-weight (generally <1000 g/mol) organic or inorganic molecules, peptides, or proteins/nucleic acids cocystallized with low-molecular-weight molecules. If chemical compounds were used, the corresponding author is further required to indicate whether the complete chemical structures of the compounds used will be disclosed at the time of presentation at the meeting. The chemical structures are not required to be included at the time of abstract submission; rather, an indication of the intent to disclose any such structures at the time of presentation is required.

The Program Committee will then evaluate the information provided by the corresponding author and determine the acceptability of the proffered paper for presentation. Those who do not intend to disclose chemical structures may have their abstracts rejected for participation; however, a limited number of these abstracts without chemical structures may be accepted for presentation if deemed to be of sufficient scientific merit.

**Submission Fee.** Each abstract submitted must be accompanied by a $65 abstract submission fee. The submission fee can be paid by credit card or check. The fee is nonrefundable regardless of the final disposition of the abstract.

**Abstract Deadline.** The deadline for abstract submissions is 11:59 p.m. U.S. ET, Thursday, November 19, 2020. Abstracts submitted after the deadline will not be considered by the Program Committee. **No significant changes may be made to abstracts after the November 19, 2020, deadline.**

**Note:** Submitting an abstract for presentation at the AACR Annual Meeting 2021 does not constitute registration for the meeting. Abstract presenters must register to attend the meeting at AACR.org/AACR2021.

**Late-Breaking Abstract Deadline.** The deadline for late-breaking abstracts is 11:59 p.m. U.S. ET, Monday, January 11, 2021. Abstracts detailing highly significant and timely findings in any area of cancer research that were not available at the time of the regular abstract deadline will be considered for presentation at the Annual Meeting. Only those abstracts that are deemed to be of high scientific priority will be accepted.

Abstract submission fees and sponsorship regulations also apply to late-breaking abstracts.

**Clinical Trials Abstract Deadline.** All abstracts describing clinical trials (including placeholder abstracts) should be submitted as late-breaking abstracts. The deadline for clinical trials abstracts is 11:59 p.m. U.S. ET, Monday, January 11, 2021. Final data for placeholder abstracts are due Thursday, February 4, 2021 (see page 9). Abstract submission fees and sponsorship regulations also apply to clinical trials abstracts.

**Publication Opportunity.** For consideration of simultaneous publication in an AACR journal, please contact the AACR Publishing Division at pubs@aacr.org.

**Presentation of Proffered Papers at the AACR Annual Meeting.** Every proffered abstract that has been accepted for publication in the online *Proceedings* must have a corresponding presentation at the meeting. Specifically, the author listed as the presenter for an accepted proffered paper must attend the corresponding session to discuss in detail the research outlined in the published abstract, according to the specific guidelines of the session. Presentation formats for 2021 include ePosters with enhanced engagement and networking opportunities and short talks in minisymposia. If, due to unforeseen circumstances, the designated presenter is unavailable to attend the session to present the paper, he or she must contact the AACR Program Development Department to designate a coauthor to serve as the presenter. If no abstract authors are available to present the data, the presenter must withdraw the abstract immediately by contacting the AACR Program Development Department at 215-440-9300 or abstractchanges@aacr.org. Failure to comply with these regulations pertaining to abstract presentation may result in actions including, but not limited to:
The withdrawal of the abstract from the session
The removal of the abstract from the online Proceedings
The loss of future sponsorship privileges for the sponsor of the abstract
The loss of future abstract submission/authorship privileges for the presenter of the abstract

Deadline for Withdrawal of Abstracts. Requests to withdraw regular abstracts will be accepted through Monday, February 22, 2021. Requests to withdraw late-breaking or clinical trials abstracts will be accepted through Tuesday, March 9, 2021. Withdrawal requests must be sent by email to abstractchanges@aacr.org. Withdrawal requests must include the Abstract Control Number and title as well as an explanation of the reason for withdrawal.

ABSTRACT SPONSORSHIP REGULATIONS

Expanded Abstract Sponsorship Privileges for AACR Members

Expanded abstract sponsorship privileges for selected AACR member types are available for the AACR Annual Meeting 2021, as outlined below:

★ Active, Honorary, and Emeritus Members may now sponsor an unlimited number of abstracts for presentation at the meeting. (As always, members must verify the content, authenticity, and quality of the abstracts they agree to sponsor.)

★ Affiliate Members are still permitted to sponsor one abstract for each deadline provided that they are the presenter of the abstract. However, Affiliate Members are no longer required to provide an endorser for their abstract.

Members must be in good standing in order to sponsor and endorse abstracts for presentation (see below for details). To be in good standing for the November 19 regular abstract deadline, member dues must be paid in full through 2020. To be in good standing for the January 11 late-breaking and clinical trials abstract deadline, member dues must be paid in full through 2021. Associate, Honorary, and Emeritus Members are exempt from the payment of dues; therefore, this regulation does not apply to them.

1. Each abstract submitted for presentation at the AACR Annual Meeting must be sponsored by an Active, Emeritus, Honorary, Affiliate, or Associate AACR Member in good standing. (Student members are not eligible to sponsor an abstract.)

2. An Active, Emeritus, or Honorary Member may sponsor an unlimited number of abstracts and may use his or her sponsorship privileges in two ways: (a) to sponsor abstracts on which he or she is listed as an author, or (b) to sponsor abstracts submitted by colleagues on which he or she is not listed as an author.

3. An Associate Member in good standing may sponsor one abstract for each submission deadline provided that (a) he or she is the presenter of the abstract, and (b) an Active, Emeritus, or Honorary Member in good standing endorses the work. Active, Emeritus, and Honorary Members may endorse an unlimited number of abstracts while still retaining their right to sponsor an unlimited number of abstracts.

4. An Affiliate Member in good standing may sponsor one abstract for each submission deadline provided that he or she is the presenter of the abstract. (Affiliate Members are no longer required to provide an endorser.)

5. Permission to list an AACR member as a sponsor or endorser must be obtained prior to selecting the sponsor/endorser in the Online Abstract Submission System. Individuals listed as sponsors or endorsers of abstracts will receive a notification of sponsorship or endorsement via email.

6. The sponsor must verify the content, authenticity, and quality of the abstract. Sponsorship of an abstract implies support for the data and the interpretations contained therein.

COMPLIANCE WITH THESE REGULATIONS IS THE RESPONSIBILITY OF THE AUTHORS. Adherence to these rules will be strictly enforced. Violations will result in the rejection of the abstract by the Program Committee.

MEMBERSHIP APPLICATION DEADLINES FOR ABSTRACT SPONSORSHIP

Nonmember individuals interested in joining the AACR and sponsoring an abstract for Annual Meeting 2021 must submit an application for membership no later than November 12, 2020. Individuals interested in joining the AACR and sponsoring a clinical trial or late-breaking abstract must submit an application for membership no later than January 7, 2021. Membership questions may be directed to membership@aacr.org.
The 2021 abstract categories, along with their related subcategories and subclassifications, are listed below. When you use the Abstract Submission System, these options will be available for your selection. Please choose the appropriate category, subcategory, and subclassification that best describe the scientific content of the abstract and the particular scientific audience you wish to reach. This information will be utilized by the members of the Program Committee in their review of abstracts and planning of sessions at the Annual Meeting 2021. Please note that these abstract categories may or may not be used as Annual Meeting session titles. Before making your selection, please scan the entire list for the most appropriate abstract category, subcategory, and subclassification. The regular abstract submission deadline is **Thursday, November 19, 2020 (11:59 p.m. ET)** and the late-breaking and clinical trials abstract submission deadline is **Monday, January 11, 2021 (11:59 p.m. ET)**.

The AACR is committed to raising awareness about the enormous public health challenge of cancer health disparities and racial inequalities. We encourage you to view the relevant abstract subcategories and subclassifications in the listing below. Also, a new submission category, COVID-19 and Cancer, provides an opportunity to submit novel work in this timely and critically important area.

<table>
<thead>
<tr>
<th>MCB</th>
<th>Molecular and Cellular Biology, Genetics</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCB01</td>
<td>Cell Growth Signaling Pathways</td>
</tr>
<tr>
<td></td>
<td>Cell signaling</td>
</tr>
<tr>
<td></td>
<td>Growth factors</td>
</tr>
<tr>
<td></td>
<td>GTPases, their regulators, and effectors</td>
</tr>
<tr>
<td></td>
<td>Kinases and phosphatases</td>
</tr>
<tr>
<td></td>
<td>Receptors</td>
</tr>
<tr>
<td></td>
<td>Tumor-stromal cell interactions</td>
</tr>
<tr>
<td></td>
<td>Ubiquitin and ubiquitin-like proteins</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
<tr>
<td>MCB02</td>
<td>Cell Death</td>
</tr>
<tr>
<td></td>
<td>Apoptosis</td>
</tr>
<tr>
<td></td>
<td>Autophagy</td>
</tr>
<tr>
<td></td>
<td>Bcl-2 family proteins</td>
</tr>
<tr>
<td></td>
<td>Caspases</td>
</tr>
<tr>
<td></td>
<td>Effectors of apoptosis</td>
</tr>
<tr>
<td></td>
<td>Inhibitor of apoptosis (IAP) family proteins</td>
</tr>
<tr>
<td></td>
<td>Necrosis and necroptosis</td>
</tr>
<tr>
<td></td>
<td>Transcriptional control of apoptosis</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
<tr>
<td>MCB03</td>
<td>Oncogenes and Tumor Suppressor Genes</td>
</tr>
<tr>
<td></td>
<td>Cytosplastic signal transducers</td>
</tr>
<tr>
<td></td>
<td>Genotype/phenotype correlations</td>
</tr>
<tr>
<td></td>
<td>Nuclear oncoproteins and tumor suppressor genes</td>
</tr>
<tr>
<td></td>
<td>Oncogene growth factors and their receptors</td>
</tr>
<tr>
<td></td>
<td>Tumor suppressor genes</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
<tr>
<td>MCB04</td>
<td>Gene Regulation and Transcription Factors</td>
</tr>
<tr>
<td></td>
<td>Chromatin structure and function</td>
</tr>
<tr>
<td></td>
<td>Gene expression</td>
</tr>
<tr>
<td></td>
<td>Mechanisms of transcription</td>
</tr>
<tr>
<td></td>
<td>Oncogenic transcription factors</td>
</tr>
<tr>
<td></td>
<td>Posttranscriptional and translational control</td>
</tr>
<tr>
<td></td>
<td>Promoters and enhancers of transcription</td>
</tr>
<tr>
<td></td>
<td>Protein-protein interactions in transcription factor function</td>
</tr>
<tr>
<td></td>
<td>Regulation of transcription factor function</td>
</tr>
<tr>
<td></td>
<td>Transcriptional control of cell differentiation</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
</tbody>
</table>

| MCB05 | Epigenetics |
|       | Chromatin structure and function |
|       | DNA methylation |
|       | Epigenetic changes as molecular markers of cancer |
|       | Epigenomics |
|       | Gene silencing |
|       | Histone modification |
|       | Other |

| MCB06 | Cell Cycle |
|       | CDKs and CDK inhibitors |
|       | Cell cycle checkpoints |
|       | Control of cell cycle progression |
|       | Mitosis |
|       | Telomeres and telomerase |
|       | Other |

| MCB07 | DNA Damage and Repair |
|       | Chromosomal structural alterations/translocations |
|       | Genomic instability |
|       | Homologous recombination |
|       | Mechanisms of genomic alterations |
|       | Radiation-induced DNA damage |
|       | Other |

| MCB08 | Metabolism and Cancer |
|       | Metabolic pathways |
|       | Metabolomics |
|       | Mitochondrial function |
|       | Signaling pathways that regulate metabolism |
|       | Warburg effect |
|       | Other |

| MCB09 | Genomics |
|       | (See also BSB01: Bioinformatics and Computational Biology) |
|       | Functional genomics |
|       | Genomic profiling of tumors |
|       | High-throughput sequencing |

| MCB10 | microRNAs and Other Noncoding RNAs |
|       | Epigenetic control of miRNA expression |
|       | miRNA profiling in cancer |
|       | miRNA regulation of cancer biology |
|       | miRNA-based diagnostics |
|       | miRNA-based therapeutics |
|       | miRNAs as tumor suppressors/oncogenes |
|       | Noncoding RNAs |
|       | Other |

| MCB11 | Cellular Stress Responses |
|       | Hypoxia |
|       | Oxidative stress |
|       | Senescence |
|       | Unfolded protein response |
|       | Other |

<table>
<thead>
<tr>
<th>BSB</th>
<th>Bioinformatics, Convergence Science, and Systems Biology</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSB01</td>
<td>Bioinformatics and Computational Biology</td>
</tr>
<tr>
<td></td>
<td>(See also MCB09: Genomics)</td>
</tr>
<tr>
<td></td>
<td>Analytic pipeline optimization</td>
</tr>
<tr>
<td></td>
<td>Application of bioinformatics to cancer biology</td>
</tr>
<tr>
<td></td>
<td>Database resources</td>
</tr>
<tr>
<td></td>
<td>Molecular modeling</td>
</tr>
<tr>
<td></td>
<td>New algorithms</td>
</tr>
<tr>
<td></td>
<td>New software for data analysis</td>
</tr>
<tr>
<td></td>
<td>Sequence analysis</td>
</tr>
<tr>
<td></td>
<td>Statistical methods</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
</tbody>
</table>

Large-scale approaches to cancer gene discovery |
Microarrays |
Other |

Other
Other Tumor microcirculation and the Novel pro- and antiangiogenic factors Molecular mechanisms of angiogenesis Host-tumor interactions Novel pro- and antiangiogenic factors Tumor microcirculation and the microenvironment Other

TB Tumor Biology

TB01 Nonclinical Models of Cancer
3-D and tissue recombinant models Developmental phenotypes of cancer genes Human-in-mouse models of human cancer Model organisms in drug discovery Mouse models of human cancer Noninvasive imaging in animal models Organooids Patient-derived xenograft models Zebrafish models of cancer Other animal and cell models of cancer Other

TB02 Stem Cell Biology
Adult stem cells Cancer stem cells Developmental pathways in cancer Embryonic stem cells Stem cell markers Stem cells and regenerative medicine in oncology Other

TB03 Tumor Adhesion
Cell adhesion and extracellular matrix Cell-cell adhesion Drug resistance Other

TB04 Invasion and Metastasis
Actin cytoskeleton Biomarkers of metastasis Epithelial/mesenchymal transition (EMT and MET) Expression profiling of tumor progression and metastasis Genes that regulate migration and invasion Imaging of tumor progression and metastasis Invasion and migration Metastasis suppressor genes Metastasis-promoting genes Premetastatic niche Therapeutic metastasis prevention Other

TB05 Angiogenesis
Angiogenesis and angiogenesis inhibitors Host-tumor interactions Molecular mechanisms of angiogenesis Novel pro- and antiangiogenic factors Tumor microcirculation and the microenvironment Other

TB06 Tumor Microenvironment
Chemokines in the microenvironment Drug targets in the microenvironment Extracellular matrix and integrins Gene expression in the microenvironment Immune cells in the tumor microenvironment Immunity and the microenvironment Inflammatory cells as regulators of tumor growth Microbiome Organ-specific microenvironments Proteases and inhibitors in the microenvironment Tumor dormancy Tumor/stromal interactions Tumor-immune system interactions Other

TB07 In Vivo Imaging
(See also CL01: Translational Research – Molecular Biology in the Clinic) Advanced nanotechnology and imaging Application of imaging technology to the clinic Imaging in animal models Imaging of molecular and cellular events in the tumor microenvironment Imaging of molecular and cellular events in tumors and tumor cells Imaging the immune response Imaging tumor metabolism New targets for imaging Other

TB08 Pediatric Cancer - Basic Science
(See also CL02: Pediatric Cancer - Clinical Investigations; CT04: Phase I, II, or III Clinical Trials in Pediatric Cancer) Developmental origins and drivers of pediatric cancer Pediatric cancer epigenomics and genomics Pediatric cancer models Pediatric cancer tumor microenvironment and tumor heterogeneity Other

TB09 Radiation Science
(See also CL07: Radiation Oncology; ET09: Preclinical Radiotherapeutics) Modulators of radiation response Photobiology/photodynamic therapy Radiation dose fractionation Radiation-activated signaling pathways Radiation-induced gene expression Radiation-induced resistance Radiobiology research Radioprotectors and radiosensitizers Other

TB10 Tumor Evolution and Heterogeneity
Causes and consequences of tumor heterogeneity Complex adaptive systems Methods to measure tumor evolution and heterogeneity Other

TB11 Carcinogenesis
Carcinogenesis: Chemical, environmental, and molecular Mutagenesis Tumor initiation and promotion Viral-induced carcinogenesis Other

CH Cancer Chemistry

CH01 Drug Discovery, Design, and Delivery
Basic and applied nanotechnology and therapeutics Chemoinformatics, in silico screening, and computational methods Drug delivery Drug design High-throughput screening (assays and libraries) Lead identification Lead optimization Nanotechnology drug delivery Natural products Synthesis, metabolism, and disposition Other

CH02 Structural and Chemical Biology
Chemical genetics and genomics Nanotechnology in chemical biology Small molecule, protein, and nucleic acid interactions Target identification, small molecule probes, and libraries X-ray and NMR structures Other

CH03 Proteomics and Mass Spectrometry
Biological mass spectrometry and systems biology Proteomics and biomarker discovery Proteomics and signaling networks Other
## ET  Experimental and Molecular Therapeutics

| ET01  Drug Discovery | Antibody technologies  
|                  | Biochemical modulators of the therapeutic index  
|                  | Combination chemotherapies  
|                  | Differentiation therapy  
|                  | New targets  
|                  | Novel assay technology  
|                  | Novel drug delivery systems  
|                  | Targeting the tumor microenvironment in drug development  
|                  | Other  
| ET02  Mechanisms of Drug Action | Cell cycle mechanisms of anticancer drug action  
|                  | Cellular responses to anticancer drugs  
|                  | Interactions of new agents with radiation  
|                  | Role of the microenvironment in therapeutic response  
|                  | Other  
| ET03  Drug Resistance | Drug resistance in molecular targeted therapies  
|                  | Drug transport and metabolism  
|                  | Novel mechanisms  
|                  | Regulation of gene expression in drug resistance  
|                  | Reversal of drug resistance  
|                  | Other  
| ET04  Molecular Targets | Cell death pathways and treatment  
|                  | Identification of molecular targets  
|                  | Modulation of DNA repair  
|                  | Molecular classification of tumors for diagnostics, prognostics, and therapeutic outcomes  
|                  | New nonclinical models for targets  
|                  | Other  
| ET05  Pharmacology, Pharmacogenetics, and Pharmacogenomics | (See also CT01: Phase I Adult Clinical Trials)  
|                  | Cellular pharmacology  
|                  | Molecular pharmacology  
|                  | Pharmacogenetics and therapeutic response  
|                  | Pharmacogenomics  
|                  | Pharmacokinetics and pharmacodynamics  
|                  | Preclinical toxicology  
|                  | Other  
| ET06  Small Molecule Therapeutic Agents | DNA-reactive agents  
|                  | Epigenetic targets  
|                  | HDAC and methyltransferase inhibitors  
|                  | Novel antitumor agents  
|                  | Novel targets and pathways  
|                  | PI3K/AKT inhibitors  
|                  | Proteasome inhibitors  
|                  | Topoisomerases  
|                  | Tubulin agents  
|                  | Tyrosine kinase and phosphatase inhibitors  
|                  | Other  
| ET07  Biological Therapeutic Agents | (See also CL06: Immuno-oncology; ET07: Biological Therapeutic Agents)  
|                  | Antireceptors  
|                  | Apoptosis: Therapeutic manipulation  
|                  | Growth factor receptors and other surface antigens as targets for therapy  
|                  | Oncogenes, tumor suppressor genes, and gene products as targets for therapy  
|                  | Protein kinases and phosphatases as targets for therapy  
|                  | Role of microenvironment in therapeutic response  
|                  | Other  
| ET08  Gene and Vector-Based Therapy | Antisense molecules  
|                  | Gene therapy and radiation studies  
|                  | Immune modulators  
|                  | Vector systems and targeting strategies  
|                  | Other  
| ET09  Preclinical Radiotherapeutics | (See also TB09: Radiation Science; CL07: Radiation Oncology)  
|                  | Modification of radiosensitivity  
|                  | Molecular targets of radiation response  
|                  | Normal tissue/cellular stress responses to radiation  
|                  | Radioprotectors and radiosensitizers  
|                  | Radiotherapeutic combinations  
|                  | Other  

## IM  Immunology

| IM01  Tumor Immunobiology | Adaptive immunity in tumors  
|                  | Epigenetic regulation of tumor immunity  
|                  | Inflammation and cancer: Metastasis  
|                  | Inflammation and cancer: Tumor initiation and progression  
|                  | Innate immunity to tumors  
|                  | Microbiome, inflammation, and cancer  
|                  | Novel animal models  
|                  | Oncogenic pathway-mediated regulation of inflammation and tumor immunity  
|                  | Tumor antigenicity/processing and presentation  
|                  | Tumor-induced immune suppression: Extrinsic factors  
|                  | Tumor-induced immune suppression: Intrinsic factors  
|                  | Other  
| IM02  Immunotherapy, Preclinical and Clinical | (See also CL06: Immuno-oncology; ET07: Biological Therapeutic Agents)  
|                  | Adoptive cell therapy  
|                  | Combination immunotherapies  
|                  | Immune checkpoints  
|                  | Immune mechanisms invoked by other therapies including chemotherapy  
|                  | Immune mechanisms invoked by radiation therapy  
|                  | Immune monitoring/clinical correlates  
|                  | Immune response to therapies  
|                  | Immunomodulatory agents and interventions  
|                  | Inflammation, immunity, and cancer  
|                  | Modifiers of the tumor microenvironment  
|                  | Therapeutic antibodies, including engineered antibodies  
|                  | Vaccines (oncolytic and prophylactic)  
|                  | Other  

## CT  Clinical Trials

*(including Combination and Immunotherapy Trials)*

All clinical trials should be submitted by the January 11, 2021 clinical trials abstract deadline.

| CT01  Phase I Adult Clinical Trials | (See also ET05: Pharmacology, Pharmacogenetics, and Pharmacogenomics)  
| CT02  Phase II Adult Clinical Trials  
| CT03  Phase III Adult Clinical Trials  
| CT04  Phase I, II, or III Clinical Trials in Pediatric Cancer | (See also CL02: Pediatric Cancer – Clinical Investigations; TB08: Pediatric Cancer – Basic Science)  
| CT05  Phase I, II, or III Clinical Trials in the Elderly  
| CT06  Phase I, II, or III Clinical Trials in Minorities and Medically Underserved Populations  

---

**Regular Abstract Submission Deadline:** Thursday, November 19, 2020  
**Late-Breaking and Clinical Trials Abstract Submission Deadline:** Monday, January 11, 2021
CT07  Clinical Trials for COVID-19
[See also COVID06: Clinical Trials (Phase I–Phase IV and Trials in Progress)]
Phase I
Phase II
Phase III
Phase IV, observational, and expanded access
Clinical trials in progress

CT08  Clinical Trials in Progress
Phase I clinical trials in progress
Phase II clinical trials in progress
Phase III clinical trials in progress

CL  Clinical Research
[not including clinical trials; see also the Clinical Trials (CT) categories]

CL01  Translational Research – Molecular Biology in the Clinic
(See also: TB07: In Vivo Imaging)
Clinical imaging
Cyto genetics and clinical molecular genetics
Epigenetic therapy
Functional and molecular imaging
Laboratory correlates for targeted agents
Molecular classification of tumors
Radiomics
Tumor staging: Correlation of clinical and molecular markers
Other

CL02  Pediatric Cancer – Clinical Investigations
(See also CT04: Phase I, II, or III Clinical Trials in Pediatric Cancer; TB08: Pediatric Cancer – Basic Science)
Adolescent and young adult oncology
Childhood cancer drug development
Immunotherapeutic approaches to pediatric cancer
Pediatric cancer predisposition and surveillance
Surveillance, late effects, and secondary cancers
Therapeutic dosing, resistance, and combination therapy approaches in pediatric oncology
Translational pediatric cancer research
Other

CL03  Clinical Research in the Elderly
Aging, immunity, and cancer
Other

CL04  Clinical Research in Racial and Ethnic Minorities and Other Underserved Populations
Biobanking/biospecimen collection
Clinical trial design
Community engaged research/community-based participatory research
Patient accrual and retention
Patient navigation
Other

CL05  Biostatistics in Clinical Trials
Design and analysis of clinical trials
New study designs: Theory, methodology, and modeling
Statistical modeling for cancer studies
Other

CL06  Immuno-oncology
(See also ET07: Biological Therapeutic Agents; IM02: Immunotherapy, Preclinical and Clinical)
Adoptive cell therapy
Combination immunotherapies
Immune checkpoints
Immune mechanisms invoked by other therapies including chemotherapy
Immune mechanisms invoked by radiation therapy
Immune monitoring/clinical correlates
Immune response to therapies
Immuno modulatory agents and interventions
Inflammation, immunity, and cancer
Modifiers of the tumor microenvironment
Therapeutic antibodies, including engineered antibodies
Vaccines (oncolytic and prophylactic)
Other

CL07  Radiation Oncology
(See also TB09: Radiation Science; ET09: Preclinical Radiotherapeutics)
Clinical radiotherapeutic studies
Interventional radiology
Modification of radiosensitivity
Radiation-immunotherapy and other radiotherapeutic combinations
Radiation-induced late effects/secondary cancers
Radiation-induced resistance
Other

CL08  Surgical Oncology (including Prophylactic Surgery)
Surgical oncology

CL09  Clinical Endocrinology
(See also EN01: Molecular, Preclinical, and Clinical Endocrinology)
Endocrine-related cancers
Hormone receptors and diagnosis/prognosis
Hormone signaling and inhibitors
Hormone synthesis, metabolism, and inhibitors
Neuroendocrine and other endocrine factors
Nuclear receptors: Structure and function
Preclinical studies of endocrine-related cancers
Receptors and signal transduction
Steroid hormone receptors
Other

CL10  Survivorship Research and Supportive Care
Biology of cell and tissue damage
Comparative effectiveness research and cost-effective studies
Late effects and second cancers
Psycho-oncology
Supportive care, palliation, and pain management
Translational survivorship research
Other

CL11  Biomarkers
Biomarkers predictive of therapeutic benefit
Diagnostic biomarkers
Early detection biomarkers
Liquid biopsies: Circulating DNA
Liquid biopsies: Circulating tumor cells
Metastasis biomarkers
Prognostic biomarkers
Other

CL12  Clinical Outcomes Research
Clinical outcomes research

EN  Endocrinology

EN01  Molecular, Preclinical, and Clinical Endocrinology
(See also CL09: Clinical Endocrinology)
Endocrine-related cancers
Growth factors, receptors, and signal transduction
Hormone receptors and diagnosis/prognosis
Hormone signaling and inhibitors
Hormone synthesis, metabolism, and inhibitors
Neuroendocrine and other endocrine factors
Nuclear receptors: Structure and function
Preclinical studies of endocrine-related cancers
Receptors and signal transduction
Steroid hormone receptors
Other
AAPR ANNUAL MEETING 2021
ABSTRACT CATEGORIES (cont’d)

EP Epidemiology (including Genetic, Molecular, and Integrative Epidemiology)

EP01 Epidemiology
- Biomarkers of endogenous or exogenous exposures, early detection, and biologic effects
- Biomarkers of prognosis
- Cancer health disparities research
- Descriptive epidemiology, covering cancer incidence, mortality, clusters, and trends
- Diet, alcohol, tobacco use, and other lifestyle risk factors
- Environmental and occupational risk factors
- Familial and hereditary cancers
- Functional studies of genetic variants
- Gene-gene and gene-environment interactions
- Genome-wide association studies (GWAS)/post-GWAS
- Health services and comparative effectiveness research
- Infection and immune factors
- Next-generation sequencing in epidemiology studies (whole genome, exome, targeted, or fine-mapping)
- Pathway and candidate gene studies of risk or prognosis
- Pharmacoepidemiology
- Preneoplastic and tumor markers
- Primary and secondary intervention studies
- Risk prediction models for incidence, prognosis, and/or mortality
- Screening and early detection
- Statistical and epidemiological methodology
- Survivorship research
- Other

COVID COVID-19 and Cancer

COVID01 Intersection of the Biology of SARS-CoV-2 and Cancer
- Biomarkers/predictors of COVID-19 and cancer
- Host genomics and genetics
- Immunobiology
- Pathophysiology
- Viral evolution
- Other

COVID02 Diagnostics for COVID-19 Testing: Design, Development, and Validation

COVID03 Cancer Drug Repurposing to Treat COVID-19

COVID04 COVID-19 Vaccine Development

COVID05 Effects of Cancer Immunotherapies on Patients with COVID-19 (with or without Cancer)

COVID06 Clinical Trials
[See also CT07: Clinical Trials for COVID-19 (Phase I–Phase IV and Trials in Progress)]
- Phase I
- Phase II
- Phase III
- Phase IV, observational, and expanded access
- Clinical trials in progress

COVID07 Continuity of Cancer Care
- Long-term outcomes
- Novel health care strategies (including telehealth and digital health)

PR Prevention, Early Detection, and Interception

PR01 Preclinical Prevention, Early Detection, and Interception
- Animal models in prevention
- Biological and biochemical mechanisms in prevention
- Biomarkers and intervention studies
- Cellular models
- Chemoprevention studies
- Diet, nutrition, and cancer
- Microbiome and prevention
- Molecular markers in prevention research
- Molecular targets for prevention
- New agent development
- Screening and early detection
- Other

PR02 Clinical Prevention, Early Detection, and Interception
- Application of molecular pathology in clinical prevention
- Biomarkers and intervention studies
- Cancer health disparities research
- Cancer surveillance and screening studies
- Chemoprevention clinical trials

Other
- Genetic markers as surrogate endpoints in prevention trials
- Genomics and proteomics in cancer risk and response assessment
- Infections and viral-related cancers
- Microbiome and prevention
- Prevention and treatment of premalignant lesions (intraepithelial neoplasia)
- Prevention of second cancers
- Recruitment of racial and ethnic minorities and other underserved populations in clinical prevention trials
- Screening and early detection
- Other

PR03 Implementation Science
- Behavioral science and prevention
- Cancer communication and decision-making
- Cancer health disparities research
- Genetic testing and counseling
- Health policy and outcomes
- Obesity, diet, physical activity, and energy balance
- Quality of life/late effects/survivorship
- Other

RSP Regulatory Science and Policy

RSP01 Regulatory Science and Policy
- Biosimilars and generics
- Clinical trial design and accrual
- Combination therapies and codevelopment of investigational agents and diagnostics
- Data science and informatics
- Novel endpoints and biomarkers
- Real-world evidence and retrospective analyses
- Tobacco and e-cigarette regulation
- Other

SHP Science and Health Policy

SHP01 Science and Health Policy
- Cancer health disparities
- Cancer survivorship
- Comparative effectiveness research
- Implementation science
- Patient advocacy and engagement
- Value and cost issues in cancer care
- Other

 regular abstract submission deadline: Thursday, November 19, 2020
late-breaking and clinical trials abstract submission deadline: Monday, January 11, 2021

AACR.org/AACR2021 #AACR21 23
AACR MEMBERSHIP: THE ESSENTIAL ASSOCIATION FOR YOU

With over 47,000 members in 127 countries and territories around the world, the AACR is a dynamic and vibrant organization that offers its members opportunities to participate more fully in the global initiative to eliminate cancer. AACR membership is available to those who conduct cancer research and related biomedical science, both senior and early-career investigators, as well as to those health care professionals, research administrators, cancer survivors and advocates, students, and others who share the AACR’s vision and support our mission to accelerate the prevention and cure of all cancers.

AACR membership categories promote the professional growth of those in training, facilitate collaborations for established scientists, and provide support for all working in cancer research. Special rates are available to members located in countries with emerging economies as designated by the World Bank. For a complete list of countries with emerging economies, please visit AACR.org/International.

MEMBERSHIP APPLICATION DEADLINES FOR ABSTRACT SPONSORSHIP

Nonmember individuals interested in joining the AACR and sponsoring an abstract must submit an application for membership no later than November 12, 2020. Individuals interested in joining the AACR and sponsoring a late-breaking abstract must submit an application for membership no later than January 7, 2021.

ABSTRACT SPONSORSHIP

Membership Application Deadlines
November 12, 2020
January 7, 2021

Abstract Deadlines
November 19, 2020
January 11, 2021 (Late-Breaking and Clinical Trials)

SCHOLAR AWARDS

Membership Application Deadline
November 12, 2020

All Travel Awards Application Deadline
November 19, 2020

Contact the AACR Membership Department with any questions at 215-440-9300 or membership@aacr.org.

AACR MEMBERSHIP CATEGORIES

Active Membership is open to investigators worldwide who have established a record of scholarly activity resulting in original peer-reviewed articles in publications relevant to cancer research and biomedical science.

Affiliate Membership is open to qualified individuals who are health professionals working in support of cancer research and biomedical science; survivors and advocates who are members of organizations whose mission includes the advancement of cancer research; educators; or other professionals who are interested in and/or make substantial contributions to the cancer field.

Associate Membership is open to graduate students, medical students and residents, and clinical and postdoctoral fellows who are enrolled in education or training programs that could lead to careers in cancer research and the related sciences. Annual dues are not required.
**Student Membership** is open to persons who have manifested an interest in cancer and the related biomedical sciences and who are enrolled in a program leading to a high school diploma or a bachelor’s degree. Annual dues are not required.

**Sustaining Membership** is open to organizations in recognition of annual payment of dues and other substantial contributions in support of the mission, purposes, and activities of the Association. Annual dues are determined by the Sustaining Member level.

**Emeritus Membership** is open to existing Active Members who have reached the age of 70 years, who are disabled, or who are retired.

**Honorary Membership** is open to distinguished individuals who have made extraordinary contributions to the advancement of cancer research either through outstanding personal scientific activity or through exceptional leadership in cancer research. (Candidates for Honorary Membership are invited through a special selection process.)

Please contact the Membership Department at membership@aacr.org or 215-440-9300 and a membership representative will gladly assist with any questions. Not yet a member? Apply for membership at myAACR and join us in the global conquest of cancer.

“The knowledge shared by researchers all around the world helped me in understanding the current landscape of cancer research.”
ABOUT WASHINGTON, DC

Washington, DC, the nation’s capital and the political focal point of the country, hosts 176 foreign embassies as well as the headquarters of many international organizations, trade unions, nonprofit organizations, advocacy groups, and professional associations. Home to a lively urban center, Washington, DC, is a walkable city that offers a variety of dining options and numerous free attractions, museums, and historical monuments. The Georgetown Lombardi Comprehensive Cancer Center, the George Washington University Cancer Institute, the National Cancer Institute, the National Institutes of Health, the U.S. Food and Drug Administration, and other government agencies that are important to the cancer field are all located in Washington, DC, and the region.

HOUSING AND REGISTRATION

Housing and registration for AACR Annual Meeting 2021 will open in December. Additional information will be posted at AACR.org/AACR2021.

OPPORTUNITIES TO SUPPORT THE AACR FOUNDATION

The AACR Foundation welcomes support from corporations, foundations, individuals, and other organizations that share its mission and are interested in helping to defray the costs of presenting this important international meeting on the latest developments in cancer research. For a complete list of support opportunities and their many benefits, please contact Peter VanPelt, Senior Director, Corporate and Foundation Relations, at 215-446-7256 or via email at peter.vanpelt@aacr.org.

FELLOWS OF THE AACR ACADEMY

The AACR Academy was established in 2013 to honor distinguished scientists whose major scientific contributions have propelled significant innovation and progress against cancer. Those elected, known as Fellows of the AACR Academy, constitute a global brain trust of individuals who are instrumental in advancing the mission of the AACR to prevent and cure all cancers through research, education, communication, and collaboration.

The AACR Academy is currently led by Dr. Judy E. Garber and a Steering Committee of ten additional Fellows who serve as a voice for all Fellows of the AACR Academy, while providing ongoing advice and counsel to the AACR leadership on timely and significant scientific and policy topics as well as other matters of importance to the cancer field.

The next elected class of Fellows of the AACR Academy will be formally recognized in conjunction with the AACR Annual Meeting 2021 Opening Ceremony scheduled to take place on Sunday, April 11.

AACR SCIENTIFIC ACHIEVEMENT AWARDS, LECTURESHIPS, AND PRIZES

In 1961, the AACR established its first scientific achievement award, partnering with Eli Lilly and Company to present the AACR G.H.A. Clowes Memorial Award. Named for G.H.A. Clowes, a founding member of the AACR and a past research director at Eli Lilly and Company, the award was created to recognize an individual scientist for outstanding recent accomplishments in the field of basic cancer research.
More than fifty years later, the AACR continues to recognize and reward scientific excellence in all areas of cancer research by annually administering 19 different scientific achievement awards and lectureships. In addition to these awards, the AACR annually presents the AACR June L. Biedler Prize for Cancer Journalism, which since 2015 has recognized outstanding journalistic coverage that enhances the general public’s understanding of cancer science and medicine.

All 2020-2021 AACR awardees will be formally recognized throughout the AACR Annual Meeting 2021, with the majority of individuals presenting featured scientific lectures highlighting their research accomplishments. We encourage you to attend these lectures and also to nominate your colleagues for one or more of these prestigious awards at AACR.org/Awards.

SATELLITE EDUCATIONAL SYMPOSIA

Satellite Educational Symposia will be held in conjunction with the AACR Annual Meeting. These CME-accredited events are supported by parties other than AACR and are not part of the official program of the AACR Annual Meeting. Symposia are evaluated by the Satellite Educational Symposia Committee to ensure that the educational content will enhance that provided by the official AACR scientific program. Additional information will be available at AACR.org/AACR2021.

EXHIBIT SHOW

The 2021 AACR Exhibit Show will include a wide array of companies with the latest products and services for laboratory and clinical research. If your organization would like to exhibit and would like to receive an Exhibitor Prospectus, please contact the Exhibits Team at 215-440-9300 or by email at exhibits@aacr.org.

ASSISTANCE FOR PHYSICALLY CHALLENGED REGISTRANTS

The AACR Annual Meeting is accessible to all attendees. Registrants with special requirements for transportation, hotel accommodations, or other facilities connected with the meeting should notify the AACR in advance by checking the appropriate box when registering and providing the necessary details or by emailing the Meetings and Exhibits Department at meetings@aacr.org.

“Exceptional during this unexpected hard time.”

AACR VIRTUAL ANNUAL MEETINGS I AND II 2020
AACR ANNUAL MEETING 2021
COMMITTEES

AACR ANNUAL MEETING PROGRAM COMMITTEE

Chair
Charles Swanton

Vice Chairs
Lewis C. Cantley
Heather R. Christofk
Melissa B. Davis
Keith T. Flaherty
Ricky W. Johnstone
Karen E. Knudsen
Quynh-Thu Le
Jean-Charles Soria
Louis M. Staudt
David A. Tuveson

Cochairs
Peter C. Adamson
Carole L. Baas
Dafna Bar-Sagi
David L. Bartlett
Julie R. Brahmer
Javier Cortés
Riccardo Dalla-Favera
Luis A. Diaz
John F. DiPersio
Steven M. Dubinett
Tariq Enver
Douglas T. Fearon
Irene M. Gobrial
Anna R. Giuliano
W. Nicholas Haining
James R. Heath
Manuel Hidalgo
Melissa M. Hudson
Stephen D. Hursting
Christine A. Iacobuzio-Donahue
Roger S. Lo
Elli Papaemmanuil
David Pellman
Erik Sahai
Stephen P. Schoenberger
Shelley S. Tworoger
Roel Verhaak
Jane E. Visvader

AACR EDUCATION COMMITTEE

Chair
Roger S. Lo

Additional Appointments Pending

AACR CLINICAL TRIALS COMMITTEE

Cochairs
Julie R. Brahmer
Manuel Hidalgo

Members
Stephen B. Baylin
Joseph N. Contessa
Johann S. de Bono
Stephan A. Grupp
Susan Halabi
Matthew D. Hellmann
Corey J. Langer
Malcolm J. Moore
Kunle Odunsi
Pamela S. Ohashi
Suresh S. Ramalingam
Russell J. Schilder
Yu Shyr
Mark A. Socinski
Roger Stupp
Weijing Sun
Charles Swanton
Dan Theodorescu
Brian Andrew Van Tine
Ignacio I. Wistuba
Stephen Yip

Additional Appointments Pending